

## Special Issue

# New Drugs against Tuberculosis and *Mycobacterium abscessus* Infections

### Message from the Guest Editors

Mycobacterial infections represent a major challenge for anti-infective therapy, and can often only be treated inadequately with approved antibiotics. There are hardly any effective drugs available for the treatment of resistant tuberculosis and for infections with non-tuberculous mycobacteria such as *M. abscessus* and *M. avium*. The establishment of new therapy concepts and drug classes is therefore of central importance in order to shorten the duration of therapy and to enable the treatment of infections with resistant pathogens. The interaction of new predictive in vitro assays, mode of action studies and the investigation of structure–activity relationships is necessary for this, and will be addressed in this Special Issue.

### Guest Editors

Prof. Dr. Peter Imming


Department of Pharmaceutical Chemistry, Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany

Dr. Adrian Richter

Department of Pharmaceutical Chemistry, Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany

### Deadline for manuscript submissions

closed (30 April 2023)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.2  
CiteScore 7.4  
Indexed in PubMed



[mdpi.com/si/105305](https://mdpi.com/si/105305)

*Molecules*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.4  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).